Loading…

4642 Plastic or metallic stents for inoperable malignant strictures of the common bile duct? results of a randomised prospective study

The systematic use of metallic stents (MS) is hampered by their price compared to plastic stents (PS) in biliary obstruction. Aims. 1- to compare cost and efficacy of plastic stents (PS) and metallic stents (MS) in the treatment of inoperable malignant strictures of the common bile duct, 2- to defin...

Full description

Saved in:
Bibliographic Details
Published in:Gastrointestinal endoscopy 2000-04, Vol.51 (4), p.AB191-AB191
Main Authors: Kaassis, Mehdi, Burtin, Pascal, Boyer, Jean, Dumas, Remi, Ponchon, Thierry, Coumaros, Denis, Delcenserie, Remi, Canard, Jean-Marc, Fritsch, Jacques, Rey, Jean-Francois
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The systematic use of metallic stents (MS) is hampered by their price compared to plastic stents (PS) in biliary obstruction. Aims. 1- to compare cost and efficacy of plastic stents (PS) and metallic stents (MS) in the treatment of inoperable malignant strictures of the common bile duct, 2- to define predictive factors of survival of patients with inoperable malignant biliary stricture. Patients. 118 patients (mean age 75 yrs) with an inoperable malignant stricture of the common bile duct were randomized to receive PS or MS. The characteristics of the 2 groups were comparable. Comparisons were made with chi-2 tests and survival rates compared with a Cox model. Results. There was no significant difference of survival between the 2 groups. Time for first obstruction was longer in patients with PS (median not reached vs 5 months, p=0.007). Number of additional days of hospitalization (173), of days with antibiotics (237), of ERCPs (20) and of abdominal ultrasonographies (18) were significantly higher in the group treated with PS. By multivariate analysis, 2 variables were independent prognostic factors of survival: the ASA classification (p=0.03 ; RR=1.5) and the number of liver metastases (p
ISSN:0016-5107
1097-6779
DOI:10.1016/S0016-5107(00)14489-X